title: Comparison of clinical and pathological staging in head and neck squamous cell carcinoma: results from Intergroup Study ECOG 4393/RTOG 9614.
abstract: OBJECTIVE
  To compare the results of clinical and pathological staging for a large cohort of patients with head and neck squamous cell carcinoma (HNSCC) and to examine patterns and ramifications of the disparity between staging methods.
  
  
  METHODS
  Prospective inception cohort (median follow-up, 7 years).
  
  
  METHODS
  Multi-institutional cooperative group study (Eastern Cooperative Oncology Group 4393/Radiation Therapy Oncology Group 9614) involving 17 academic medical centers.
  
  
  METHODS
  A total of 560 patients with new-onset or recurrent HNSCC enrolled during a 7-year period.
  
  
  METHODS
  Surgical resection with curative intent with or without adjuvant or previous radiotherapy or chemotherapy.
  
  
  METHODS
  Clinical staging and pathological staging and the component TN tumor categories were compared with overall and disease-specific survival. Association of survival with staging was derived by means of the proportional hazards model.
  
  
  RESULTS
  Of the 501 cases in which both clinical and pathological staging was available, a disparity was found between at least 1 component tumor category assigned by the 2 methods in almost 50% of cases. Both methods showed a strong association of stage with overall survival for the cohort at large. However, pathological nodal category was a superior predictor (P < .001 vs P = .005), whereas there was an advantage to pathological tumor category in predicting disease-specific survival (P = .01).
  
  
  CONCLUSIONS
  Both staging methods are useful in predicting survival, whereas information gained at neck dissection regarding nodal metastases provides some refinement in prognostic results. These findings demonstrate the need for enhanced methods of tumor assessment and apparent benefit of data gathered at neck dissection for accurate disease assessment and stratification.
authors.affiliation: Department of Otolaryngology-Head and Neck Surgery, The Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA. wkoch@jhmi.edu
authors.forename: Wayne M
authors.initials: WM
authors.lastname: Koch
authors.forename: John A
authors.initials: JA
authors.lastname: Ridge
authors.forename: Arlene
authors.initials: A
authors.lastname: Forastiere
authors.forename: Judith
authors.initials: J
authors.lastname: Manola
mesh_terms: D000368:Aged; D000704:Analysis of Variance; D001707:Biopsy, Needle; D002294:Carcinoma, Squamous Cell / Q000401:mortality* / Q000473:pathology* / Q000628:therapy; D002423:Cause of Death; D017024:Chemotherapy, Adjuvant; D015331:Cohort Studies; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D005260:Female; D006258:Head and Neck Neoplasms / Q000401:mortality* / Q000473:pathology* / Q000628:therapy; D006801:Humans; D007150:Immunohistochemistry; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D037981:Neck Dissection / Q000379:methods; D009361:Neoplasm Invasiveness / Q000473:pathology; D009364:Neoplasm Recurrence, Local / Q000401:mortality / Q000473:pathology* / Q000628:therapy; D009367:Neoplasm Staging / Q000379:methods*; D011237:Predictive Value of Tests; D011336:Probability; D011379:Prognosis; D016016:Proportional Hazards Models; D011446:Prospective Studies; D018714:Radiotherapy, Adjuvant; D016019:Survival Analysis; D016896:Treatment Outcome; D014481:United States